Media

March 1, 2022 | In the News
Scrip Asks…What Does 2022 Hold For Biopharma? Part 4: Therapeutic Area Advances

SCRIP: High Hopes In COVID-19, Cancer, CNS, Immunology And Rare Disease

January 11, 2022 | In the News
CEO to CEO: Tips for First-time Founders

BIOSPACE: We picked the brains of 10 biotech CEOs and founders to solicit their advice for first-time founders. Here’s what they told us:

November 12, 2021 | Publication
Amphiphile-Peptide Boosting with FMC63-binding Surrogate Peptide Mimotopes Induces Activation and Potent Effector Function in CAR-T Cells Targeting CD19

Scientific Poster

November 12, 2021 | Publication
Lymph Node Targeted Boosting with Cognate Amphiphile-Peptide Vaccines Enhances TCR-T Cell Therapy to Eradicate Solid Tumors

Scientific Poster

November 12, 2021 | Publication
Drakes Dylan Lymph node targeted cognate amphiphile-peptide vaccines enhances tcr-t therapy

Audio recording

September 22, 2021 | Publication
Vaccination with a lymph node targeted Amphiphile‐CpG adjuvant promotes potent cellular and humoral immunity to SARS‐CoV‐2 protein subunit antigens

Peter DeMuth, PhD, Vice President of Research — Vaccines Summit 2021

September 9, 2021 | Publication
Approaches to Improve the Clinical Performance of Genetically Engineered T Cells
July 10, 2021 | Publication
Combined PET and Whole Tissue Imaging of Lymphatic Targeting vaccine in NHPs

Antigen accumulation in lymph nodes (LNs) is critical for vaccine efficacy, but understanding of vaccine biodistributionin humans or large animals remains limited.

March 19, 2021 | Publication
Exploiting albumin as a mucosal vaccine chaperone for robust generation of lung-resident memory T cells

Tissue-resident memory T cells (TRMs) can profoundly enhance mucosal immunity, but parameters governing TRM induction by vaccination remain poorly understood.

February 2, 2021 | Publication
A lymph node–targeted Amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2

Science Advances Martin P. Steinbuck, Lochana M. Seenappa, Aniela Jakubowski, Lisa K. McNeil, Christopher M. Haqq*, Peter C. DeMuth The profound consequences of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mandate urgent development of effective vaccines. Here, we evaluated an Amphiphile (AMP) vaccine adjuvant, AMP-CpG, composed of diacyl lipid–modified CpG, admixed with the SARS-CoV-2 Spike-2 receptor […]